Get started
Author

Gary Wilkinson

Observed names: G P Wilkinson, G. Wilkinson, Gary P. Wilkinson, Wilkinson, Gary
Institution: Bayer (Germany)
ORCID: 0000-0003-1949-6205
Observed ORCID: 0000-0003-1949-6205
OpenAlex ID: A5064572702
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent
2018 · Kevin M. Foote, J. Willem M. Nissink, et al. · Journal of Medicinal Chemistry · 332
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
2020 · Timothy A. Yap, David S.P. Tan, et al. · Cancer Discovery · 263
Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies
2019 · Christian Zurth, Mikko Koskinen, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 105
PDF
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity
2019 · Sophie Postel-Vinay, Karin Herbschleb, et al. · European Journal of Cancer · 103
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
2020 · Michael Heuser, Neil Palmisiano, et al. · Leukemia · 58
PDF
Abstract 2348: Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients.
2013 · Clifford D. Jones, Kevin Blades, et al. · Cancer Research · 36
First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.
2019 · Johann S. De Bono, David Shao Peng Tan, et al. · Journal of Clinical Oncology · 30
Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent
2004 · Gary P. Wilkinson, James P. Taylor, et al. · Investigational New Drugs · 20
Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment
2021 · Christian Zurth, Pirjo Nykänen, et al. · Clinical Pharmacokinetics · 17
PDF
Abstract CT006: Phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response (DDR) defects
2022 · Timothy A. Yap, David S. Tan, et al. · Cancer Research · 15
First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies
2016 · S. Postel-Vinay, K. Herbschleb, et al. · European Journal of Cancer · 15
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy
2019 · Andreas Schneeweiss, Dagmar Hess, et al. · Cancers · 14
PDF
Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
2025 · Timothy A. Yap, David S.P. Tan, et al. · Cancer Discovery · 12
First-in-Human Dose-Escalation Study of the First-in-Class PDE3A–SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A
2024 · Kyriakos P. Papadopoulos, Meredith McKean, et al. · Clinical Cancer Research · 12
PDF
Discovery of a series of 2-(pyridinyl)pyrimidines as potent antagonists of GPR40
2015 · Michael J. Waring, David J. Baker, et al. · MedChemComm · 11
Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes
2013 · D J Baker, A M Atkinson, et al. · British Journal of Pharmacology · 11
Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes
2013 · D J Baker, G P Wilkinson, et al. · British Journal of Pharmacology · 11
Matched triplicate design sets in the optimisation of glucokinase activators – maximising medicinal chemistry information content
2013 · Michael J. Waring, Stuart N. L. Bennett, et al. · MedChemComm · 11
Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies.
2019 · Christian Zurth, Kristina Graudenz, et al. · Journal of Clinical Oncology · 9
Optimising pharmacokinetics of glucokinase activators with matched triplicate design sets – the discovery of AZD3651 and AZD9485
2013 · Michael J. Waring, Stuart N. L. Bennett, et al. · MedChemComm · 8
Optimization of treatment schedule for the ATR inhibitor elimusertib (BAY 1895344) in preclinical tumor models
2022 · A. Wengner, L. Ehresmann, et al. · European Journal of Cancer · 3
PDF
An open-label, Phase 2 study of dapolsertib (MEN1703, SEL24) as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
2025 · Herve Ghesquieres, Malgorzata Krawczyk-Kulis, et al. · Blood · 1
PDF
Data from First-in-Human Dose-Escalation Study of the First-in-Class PDE3A–SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A
2024 · Kyriakos P. Papadopoulos, Meredith McKean, et al. · 1
Trial in Progress: An Open-Label Clinical Trial of RVU120 As Monotherapy and in Combination with Ruxolitinib in Patients with Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61)
2024 · Rostislav Kuklík, Adam Falkowski, et al. · Blood · 1
PDF
River-52: A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
2024 · Cristina Papayannidis, Krzysztof Mądry, et al. · Blood · 1
PDF
Works count: 56
Citation count: 1,104
H-index: 12
I10-index: 18
Year
Topic
Type